Fig 1: Integrations of drug sensitivity data with in molecular docking analyses to identify candidate drugs targeting the FLT1‐centered regulatory network. (A) IPS score of patients with ccRCC with low‐ and high‐VEGFA/FLT1/AKT1 axis expression in the CTLA4‐ PD1‐, CTLA4‐ PD1+, CTLA+ PD1‐, and CTLA+ PD1+ subgroups. (B) Candidate FDA‐approval drugs of the FLT1‐centered regulatory network. (C) Binding energy of FLT1‐related drugs. (D‐O) Molecular docking simulating the combine effects of drugs between the FLT1‐centered regulatory network and key drugs. (P) Gibbs Energy landscape diagrams show the stability of FLT1–Fruquintinib complexes. (Q) Gibbs Energy landscape diagrams show the stability of FLT1–Lenvatinib complexes. (R) Gibbs Energy landscape diagrams show the stability of FLT1–Pazopanib complexes. (S) Gibbs Energy landscape diagrams show the stability of FLT1–Regorafenib complexes. (T) Gibbs Energy landscape diagrams show the stability of FLT1–Sorafenib complexes. (U) MMGBSA of FLT1‐related drugs. (V–Z) Line plots present dynamic simulation metrics (e.g., RMSD, Gyrate, hydrogen bond numbers, RMSF, SASA) over time. *p < 0.05, **p < 0.01, and ***p < 0.001.